credits: The Weather Channel
The launch of the Novavax COVID-19 vaccine is probably going to be delayed further because the Serum Institute of India (SII) is yet to receive raw materials from the US despite the top on the export ban.
SII is yet to receive raw materials from the US needed to supply the Novavax vaccine, Mint reported citing a politician conscious of the event .
Earlier the CEO of SII, Adar Poonawalla, stated that Novavox vaccine against COVID-19 might be launched in September.
The pharma company is additionally getting to start clinical trials of Covovax for youngsters in July.
“It will soon apply to the drug regulator to approve the vaccine’s trial on children,” Poonawalla added. Serum Institute, which has partnered with Novavax, is additionally conducting bridge trials on the jab. The Pune-based vaccine maker will manufacture the vaccine not just for India except for dozens of lower and middle-income countries through Covax, the worldwide alliance aimed toward accelerating the event , production and equitable access to COVID-19 vaccines.
The US-based drug company had on Flag Day announced that its COVID-19 vaccine had passed the efficacy test with a score of 90.4 percent, meeting the first target of its pivotal Phase 3 trial.
The protein-based vaccine, called NVX-CoV2373, demonstrated one hundred pc protection against moderate and severe sorts of viral disease, Novavax said, adding that the vaccine scored 93.2 percent in efficacy trials on variants of the virus.